Theravance, Inc.

Theravance Biopharma R&d Ip, LLC

Dice Alpha, Inc.

Advanced Medicine, Inc.

Stategics, Inc.

Axys Pharmaceuticals, Inc.

Timothy J Church

John R Jacobsen

Sabine Axt

Thomas E Jenkins

Daisuke Roland Saito

Priscilla M Van Dyke

Yu-Hua Ji

Daniel D Long

Martin Sheringham Linsell

Lan Jiang

Paul Ross Fatheree

J Kevin Judice

Wouter Van Der Linden

Claudio Aquino

Margot G Paulick

Michael Robert Leadbetter

Eric L Stangeland

James Bradley Aggen

Edmund J Moran

Lori Jean Patterson

Jeffrey R Spencer

Huiwei Wu

Witold Hruzewicz

Seok-Ki Choi

Daniel Marquess

John H Griffin

Juha Punnonen

Bryan A Frieman

Sean Gary Trapp

Ioanna Stergiades

Matthew B Nodwell

James L Miller

David Beattie

Scott Armstrong

Connie S Tettenborn

Karen Lariosa-Willingham

Viengkham Malathong

Sean Dalziel

Kenneth D Rice

Joane Litvak

Leticia Maria Preza

Anthony R Gangloff

David C Green

Witold N Hruzewicz

Neil Scott Cutshall

Vivian R Wang

Dmitri Leonoudakis

Dimitri Leonoudakis

The disclosure herein provides compounds and pharmaceutical compositions of the structure of the following formula: for the modulation of IL-17A. useful for the treatment of inflammatory conditions, such as psoriasis.

Substituted benzenecarboxamides as IL-17A modulators

Provided herein are novel ligands and pharmaceutical compositions thereof which modulate IL-17A. Also provided are methods for preparing the IL-17A modulators. Such compounds may be useful in the treatment and/or prevention of, for example, inflammation, cancer or autoimmune disease.

IL-17 ligands and uses thereof

The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase, or a salt such as a diphosphate, monosulfate or dioxalate salt. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and intermediates for preparing the crystalline compounds; and methods of using these compounds to treat a pulmonary disorder.

Crystalline forms of a biphenyl compound

The disclosure herein provides compounds and pharmaceutical compositions for the modulation of IL-17A useful for the treatment of inflammatory conditions, such as psoriasis.

Disclosed herein are erythropoietin-mimetic compounds of Formula I, which modulate the survival, function, or differentiation of, for example, kidney cells, neurons, erythroid cells, or other erythropoietin-responsive cells. The present invention also relates to compounds and methods that preferentially modulate cells expressing the tissue-protective erythropoietin receptor. The compounds of the invention are useful in preventing and treating diseases, such as anemia, organ injury, and diseases of the central nervous system, and as an adjunct to cellular treatments, such as stem cell therapies. 

Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival

Substituted triazolo-pyrimidine compounds for modulating cell proliferation  differentiation and survival

In one aspect, the invention relates to compounds of formula I: where a and Rare as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

3-(phenoxyphenylmethyl)pyrrolidine compounds

The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula wherein R, R, R, and a are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

The invention provides 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds of formula (I): wherein R, R, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists

Growing community of inventors

San Mateo, CA, United States of America

Timothy J Church